Results 251 to 260 of about 344,927 (283)
Functional Variation in RGS12 Should Not Preclude Methylphenidate Use in Bipolar Disorder with Established Mood Stabilization: Preclinical Evidence. [PDF]
Int J Mol SciAgogo-Mawuli PS +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current Biology, 2022
Dopamine was first described by George Barger, James Ewens, and Henry Dale in 1910 as an epinephrine-like monoamine compound. Initially believed to be a mere precursor of norepinephrine, it was mostly ignored for the next four decades (Figure 1A). However, in the 1950s Kathleen Montagu showed that dopamine occurred in the brain by itself, and a series ...
Kauê Machado, Costa +1 more
openaire +2 more sources
Dopamine was first described by George Barger, James Ewens, and Henry Dale in 1910 as an epinephrine-like monoamine compound. Initially believed to be a mere precursor of norepinephrine, it was mostly ignored for the next four decades (Figure 1A). However, in the 1950s Kathleen Montagu showed that dopamine occurred in the brain by itself, and a series ...
Kauê Machado, Costa +1 more
openaire +2 more sources
Dopamine and non-dopamine psychoses
Psychopharmacology, 1984The time course of antipsychotic response following the initiation of an antipsychotic drug and functional dopamine receptor sensitivity were explored in a cohort of recently admitted psychotic (mood-incongruent) patients. The distribution of the latencies of antipsychotic response suggested at least two populations.
D L, Garver +4 more
openaire +2 more sources
Seminars in Neurology, 2001
Dopamine agonists provide an effective means of treating early, middle, and late stages of Parkinson's disease. This article outlines the advantages and disadvantages of dopamine agonists as compared with levodopa therapy. The features and costs of the four Food and Drug Administration-approved agonists (bromocriptine, pergolide, pramipexole, and ...
P, Tuite, B, Ebbitt
openaire +2 more sources
Dopamine agonists provide an effective means of treating early, middle, and late stages of Parkinson's disease. This article outlines the advantages and disadvantages of dopamine agonists as compared with levodopa therapy. The features and costs of the four Food and Drug Administration-approved agonists (bromocriptine, pergolide, pramipexole, and ...
P, Tuite, B, Ebbitt
openaire +2 more sources
Science, 1997
Ingrid Wickelgren's Special News Report “Getting the brain's attention” ([3 Oct., p. 35][1]) presents the views of those who question the current orthodoxy that dopamine acts in the nucleus accumbens as a key neurotransmitter underlying the behavioral effects of positive reinforcement or ...
J A, Gray, A M, Young, M H, Joseph
openaire +2 more sources
Ingrid Wickelgren's Special News Report “Getting the brain's attention” ([3 Oct., p. 35][1]) presents the views of those who question the current orthodoxy that dopamine acts in the nucleus accumbens as a key neurotransmitter underlying the behavioral effects of positive reinforcement or ...
J A, Gray, A M, Young, M H, Joseph
openaire +2 more sources
The Lancet, 1976
The antipsychotic actions and extra-pyramidal side-effects of neuroleptic drugs are strongly correlated with their ability to block central dopaminergic transmission. It is argued that the former are more closely related to actions on dopaminergic mechanisms in the "mesolimbic dopamine" system, and the latter to similar actions in the striatum ...
Crow, T J +3 more
openaire +4 more sources
The antipsychotic actions and extra-pyramidal side-effects of neuroleptic drugs are strongly correlated with their ability to block central dopaminergic transmission. It is argued that the former are more closely related to actions on dopaminergic mechanisms in the "mesolimbic dopamine" system, and the latter to similar actions in the striatum ...
Crow, T J +3 more
openaire +4 more sources
Medical Clinics of North America, 1999
Dopamine agonists have been used in the treatment of Parkinson's disease (PD) since the mid 1970s. With the approval of two new agents in 1997, the number available in the United States is up to four; bromocriptine, pergolide, pramipexole, ropinirole.
openaire +2 more sources
Dopamine agonists have been used in the treatment of Parkinson's disease (PD) since the mid 1970s. With the approval of two new agents in 1997, the number available in the United States is up to four; bromocriptine, pergolide, pramipexole, ropinirole.
openaire +2 more sources
Journal of Psychiatric Research, 1974
Publisher Summary The activity of the Dopamine-β-hdyroxylase (DBH) can be influenced by the activity of the citric acid cycle as well as by the activity of enzymes that either syphon off or feed in cycle intermediates. The alpha-ketoglutarate transaminases and the concentration of their amino acid substrates, for example, alanine and aspartate, and ...
openaire +2 more sources
Publisher Summary The activity of the Dopamine-β-hdyroxylase (DBH) can be influenced by the activity of the citric acid cycle as well as by the activity of enzymes that either syphon off or feed in cycle intermediates. The alpha-ketoglutarate transaminases and the concentration of their amino acid substrates, for example, alanine and aspartate, and ...
openaire +2 more sources